… of higher doses of β-lactams than FDA approved to reach clinically therapeutic exposures.
Select case reports utilizing TDM of β-lactams in complex patients are summarized in Table 2. …

… We included all randomised trials that compared treatment with any β lactam alone with
any combination of a β lactam and an aminoglycoside, for the empirical treatment of patients …

… Thus, an empirical therapy for treating infections is imperative in such a setting. The beta
lactam antibiotics have been widely used for the empirical treatment of infections since the the …

… that factors such as diverse patient populations and study methodology, along with various
antibiotic dose regimens, may have contributed to conflicting data on EI beta-lactam therapy. …

… moxifloxacin and β-lactam-based standard therapy. This meta… and safely as β-lactam-based
standard therapy for CAP but … be a useful alternative for β-lactam-based standard therapy. …

… Another reason to set a “floor” for the beta-lactam therapeutic range is to identify the lower …
observed with standard therapy ( 13 , 14 ). The current approach to beta-lactam dosing in ICU …

… /β-lactam combination therapy with β-lactam monotherapy … β-Lactam monotherapy
was not associated with a greater emergence of resistance than was the aminoglycoside/β-lactam …

… Some clinical data suggest that maximal killing of bacteria by β-lactams occurs when serum
… To achieve optimal bactericidal activity, the adequacy of β-lactam therapy in our study was …

… Hence, we believe it is important that β-lactam based combination therapy is not adopted
as standard clinical practice for MRSA bacteremia until and unless stronger evidence of safety …

… of β-lactam antibiotics may have advantages over standard … use of prolonged-infusion
β-lactams in the treatment of many … prolonging the infusion of β-lactam antibiotics and provides …